If there's one thing we know about retail investors - it's that...

If there's one thing we know about retail investors - it's that they tend to overreact (and to act, when it's sometimes best to do nothing). This has been oversold. RAD still has one of the deepest pipelines on the ASX.

The recent CR was confusing - but it may turn out to be a good move if the macroeconomic environment takes a turn for the worse in 12-18 months and raising funds becomes a lot more difficult.

Re: the IPO - yes, it's not a great situation. I feel for long term holders. But, it's very common for stocks to return to, and often dip well below, their IPO price in a short time frame after listing. And as it's been discussed, the entire biotech sector has copped a hit in the past 12 months and I can't see this changing any time soon.

So, my plan, given all of the above, is to accumulate when I can and otherwise, sit tight and wait. All IMO DYOR